Potential life years not saved due to lack of access to anti-EGFR tyrosine kinase inhibitors for lung cancer treatment in the Brazilian public healthcare system: Budget impact and...

por Aguiar, Pedro, Barreto, Carmelia Maria Noia, Roitberg, Felipe, Lopes, Gilberto, del Giglio, Auro
Publicado 2020

Cost effectiveness of chemohormonal therapy in patients with metastatic hormone-sensitive and non-metastatic high-risk prostate cancer

por Aguiar, Pedro Nazareth, Barreto, Carmélia Maria Noia, Gutierres, Bárbara de Souza, Tadokoro, Hakaru, Lopes, Gilberto de Lima
Publicado 2017

Immune checkpoint inhibitors for advanced non-small cell lung cancer: emerging sequencing for new treatment targets

por Aguiar, Pedro Nazareth, De Mello, Ramon Andrade, Barreto, Carmelia Maria Noia, Perry, Luke Alastair, Penny-Dimri, Jahan, Tadokoro, Hakaru, Lopes, Gilberto de Lima
Publicado 2017

Cost-effectiveness analysis of abiraterone, docetaxel or placebo plus androgen deprivation therapy for hormone-sensitive advanced prostate cancer

por Aguiar, Pedro Nazareth, Tan, Pui San, Simko, Sarah, Barreto, Carmelia Maria Noia, Gutierres, Bárbara de Souza, del Giglio, Auro, Lopes, Gilberto de Lima
Publicado 2019

A paradigm shift for the treatment of hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2−) advanced breast cancer: a review of CDK inhibitors

por Fernandes, Mariane Teodoro, Adashek, Jacob J, Barreto, Carmelia Maria Noia, Spinosa, Ana Cláudia Barbin, de Souza Gutierres, Barbara, Lopes, Gilberto, del Giglio, Auro, Aguiar, Pedro Nazareth
Publicado 2018